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HPV vaccineHuman papillomaviruses (HPV) are small oncogenic DNA viruses of which more than 200 types have
been identiﬁed to date. A small subset of these is etiologically linked to the development of anogenital
malignancies such as cervical cancer. In addition, recent studies established a causative relationship
between these high-risk HPV types and tonsillar and oropharyngeal cancer. Clinical management of cer-
vical cancer and head and neck squamous cell carcinomas (HNSCCs) is largely standardized and involves
surgical removal of the tumor tissue as well as adjuvant chemoradiation therapy. Notably, the response
to therapeutic intervention of HPV-positive HNSCCs has been found to be better as compared to HPV-
negative tumors. Although the existing HPV vaccine is solely licensed for the prevention of cervical can-
cer, it might also have prophylactic potential for the development of high-risk HPV-associated HNSCCs.
Another group of viruses, which belongs to the beta-HPV subgroup, has been implicated in nonmelanoma
skin cancer, however, the etiology remains to be established. Treatment of HPV-induced nonmelanoma
skin cancer is based on local excision. However, topically applied immune-modulating substances repre-
sent non-surgical alternatives for the management of smaller cutaneous tumors. In this review we pres-
ent the current knowledge of the role of HPV in cancer development and discuss clinical management
options as well as targets for the development of future intervention therapies.
 2013 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy
and Oncology 108 (2013) 397–402
Open access under CC BY-NC-ND license.Papillomaviruses (PVs) are commonly known to cause benign
papillomas as well as epithelial malignancies. PVs are small non-
enveloped viruses with a diameter of approximately 55 nm and a
double-stranded circular DNA genome comprising almost 8000
nucleotide base pairs. The genome is arranged into the upstream
regulatory region (URR) and nine to ten open reading frames
(ORFs) encoding the viral early and late genes. Late gene expres-
sion produces the structural proteins L1 and L2, which assemble
into the viral capsid structure, whereas early gene activity trans-
lates into the regulatory proteins E1–E8. PVs generally infect kerat-
inocytes within the basal layer of stratiﬁed epithelia by gaining
access through wounds within the skin and mucosa. Initial attach-
ment to the cell surface has largely been attributed to rely on hep-
aran sulfate proteoglycans [36]. Subsequent conformational
changes within L2 result in furin-dependent cleavage of its N-ter-
minal sequence [65]. The current model of cellular entry involves a
novel actin-dependent, but clathrin-, cavoelin-, cholesterol- and
dynamin-independent pathway related to macropinocytosis
[20,71]. Woodham et al. suggest a ligand-induced mechanism inwhich pre-entry binding of the capsid proteins to integrins may
activate signaling cascades that recruit the annexin A2 heterodi-
mer to the cell membrane, which then facilitates internalization
of the virus [84]. Viral entry and posterior replication are largely
contingent on keratinocyte differentiation.
Human papillomaviruses (HPV) are classiﬁed depending on
their tissue tropism. Alpha-HPVs infect mucosal tissue whereas
beta-, gamma-, nu- and mu-subtypes infect cutaneous sites [17]
(see http://pave.niaid.nih.gov for detailed phylogeny). In addition,
mucosal HPVs are distinguished by their potential to cause malig-
nant progression. Low-risk HPVs include HPV 6, 11, 40, 42, 43, 44
54, 61, 70, 72 and 81 [62] which can cause low-grade lesions such
as condylomas and benign cervical lesions and are rarely found in
malignancies [83]. High-risk HPVs including HPV 16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59 and 66 gained notoriety by being the pri-
mary causative agents of cervical carcinoma [14,72].
Alpha-HPV-associated cancer development and therapy
Each year, 0.5 million new cases of cervical cancer are reported
with 274,000 associated deaths worldwide [5]. Certain high-risk
HPV types, recognized as class I carcinogens by the World Health
Organization, are necessary risk factors for the development of cer-
vical cancer [14,39,72]. Early stages (I–IIa) of cervical cancer can be
398 Human papillomaviruses and cancertreated rather successfully, but locally advanced cancers are char-
acterized by high recurrence rates and a poor prognosis. The stan-
dard therapy of locally advanced cervical cancer is a combination
of radiotherapy and cisplatin-based chemotherapy with an overall
5-year survival of less than 50%. Patients with stage IV or recurrent
cervical cancer treated with cisplatin alone or in combination with
topotecan only have a median survival of less than one year [57].
Despite widespread screening for cervical cancer, this disease con-
tinues to claim large numbers of lives, particularly among medi-
cally underserved populations of women. In addition to cervical
carcinoma, high-risk HPVs were found in 26% of head and neck
squamous cell carcinomas (HNSCCs) despite the main risk factors
being tobacco, alcohol, poor oral hygiene and genetic pre-disposi-
tion [44]. It has previously been shown that patients suffering from
alcohol- or tobacco-induced HNSCC are at reduced risk of simulta-
neously contracting HPV-based HNSCC [4,15]. This may be
explained by a recent ﬁnding that increased levels of the annexin
A2 ligand, secretory leukocyte protease inhibitor (SLPI), are typical
for tumors induced by smoking [28]. High expression of SLPI in
turn inhibits annexin A2, which is essential for viral entry into
the host cell [84].
Within the heterogeneous group of HNSCCs, almost 70% of all
tonsillar and oropharyngeal carcinoma cases are HPV-positive in
economically developed countries [43,52,66]. Regardless of this
knowledge there is no screening routine available in order to detect
early HPV lesions in the tonsils and oropharynx. Clinical manage-
ment is largely standardized across the HPV-positive and -negative
tumor types and stages of progression. Treatment of stage I and II
oropharyngeal cancers usually involves surgery accompanied by
radiotherapy.More locally advanced cancers are surgically removed
and treated by chemoradiation therapy [51]. It is generally accepted
that HPV-positive HNSCCs have a signiﬁcantly better prognosis as
compared to HPV-negative tumors. Patients with HPV-positive
tumor status who do not consume tobacco or alcohol presented
with a reportedly higher survival rate probably due to increased
sensitivity to chemo- and radiotherapy [52]. Several studies show
that young individuals seem to be at greater risk for developing
HPV-positive tonsillar or oropharyngeal cancers [11,27], with one
study reporting a higher percentage of cases in young men [27].
The young age of the risk groupmay be a result of changes in sexual
behavior such as earlier onset of sexual activity and increased oral
practices. These patients also exert better responses to intervention
therapy and have fewer recurrences as compared to age-matched
patients with HPV-negative HNSCCs [52].
Since 2006 two recombinant vaccines against human papillo-
mavirus types 6, 11, 16, and 18 are available. Although this is an
important step in the battle against cervical cancer, the viral types
for which these vaccines provide protection are responsible for
only 70% of the cases of cervical cancer [39]. However, it has been
shown that the vaccines confer cross protection against HPV types
31, 45 and 52 (reviewed by [6]). It is worth noting that in more
than 95% of HPV-positive tonsillar and oropharygeal cancers the
high-risk types HPV 16 and 18 were detected [44] and a prophylac-
tic vaccine regime may be the key in preventing HPV-based head
and neck cancers. Currently there are no data available evaluating
the efﬁcacy of HPV-vaccination for preventing oral cancers. Even
though vaccination may prevent HPV-associated cancers, previous
assumption was that it will provide no protection for individuals
who already have been exposed to high-risk HPV types. However,
recent research demonstrates a 67% efﬁcacy of the quadrivalent
vaccine Gardasil in seropositive, but HPV DNA-negative women
aged 24–45 years [10]. Nevertheless, the need for signiﬁcant
advances in the diagnosis and treatment of HPV-dependent can-
cers will persist.
By better understanding the course of high-risk HPV infection,
new approaches for clinical management of both cervical carci-noma and HNSCCs may be discovered. The normal productive PV
life cycle is tightly linked to keratinocyte differentiation where
the genome undergoes episomal replication generating infectious
viral particles. Persistent infection with high-risk types, however,
may lead to the integration of viral DNA into the host cell genome,
which is accompanied by a deletion of the genes encoding the viral
replication regulators E1 and E2. The expression of E2 proteins has
been described to repress the transcription of the viral oncogenes
E6 and E7 [21]. Therefore, loss of the E2 region during integration
may lead to the constitutive activation of both oncogenes thereby
fostering carcinogenesis. However, recent reports demonstrate
that in approximately 35% of cervical cancer patients full-length
viral genomes are present and actively transcribed raising the pos-
sibility of E2-expression in addition to E6 and E7-proteins within
cervical cancer cells [40,50]. E6 and E7 of HPV16 and 18 interact
with a large number of host cell proteins in order to manipulate
cell proliferation, senescence and apoptosis (Fig. 1). The E6-pro-
teins of high-risk HPV interact with the p53 tumor suppressor
and induce its proteolytic degradation [70]. In addition, HPV 16
E6-protein has been shown to induce telomerase activity [41]. Both
functions as well as E6-induced transcriptional changes in HPV-
positive cells were reported to be dependent on the ubiquitin-
ligase E6-associated protein (E6AP) [69]. Finally, E6-proteins of
high-risk HPVs share a conserved C-terminal domain, which medi-
ates its interaction with PDZ (PSD-95, Dlg, Zo-1) domain-contain-
ing proteins such as hDlg [38,48], MAGI-1 [26], hScrib [63],
MUPP1 [47] and PTPN3 [35] which are involved in epithelial cell
polarity [54,59]. E7 interacts with the retinoblastoma-family
tumor suppressor proteins pRb [24,61,73], p107 [46] as well as
p130 [16] and disrupts their interaction with E2F transcription fac-
tors, resulting in the activation of E2F-dependent gene expression
and cell cycle progression [7,53,56]. One of the proteins up-regu-
lated upon pRb degradation is p16, which is encoded by the
sequence of the CDKN2a gene [37]. An accumulation of p16 was
reported in HPV-positive cancers and serves as a prognostic marker
for intervention therapy responses [42,55]. Expression of E6 and E7
transcripts is controlled by both cellular and viral transcription fac-
tors. Interestingly, E6 and E7 also act as potent mitotic mutators,
thereby increasing the occurrence of mutations that contribute to
carcinogenic progression (reviewed in [54]). These multiple inter-
actions with important cellular pathways of the host cell may rep-
resent potential targets for developing speciﬁc therapeutic
alternatives for HPV-based cancer treatment. Other intervention
therapy approaches may arise from the fact that normal cells and
tumor cells markedly differ in their energy metabolism. When glu-
cose is metabolized in normal cells in the presence of adequate
oxygen, the process results in complete oxidation of glucose and
involves cytoplasmic glycolysis as well as mitochondrial citric acid
cycle and electron transport chain/oxidative phosphorylation. In
contrast, tumor cells rely mostly on the conversion of glucose into
lactate rather than mitochondrial oxidation for energy production.
The mitochondrial function is suppressed in most tumor cells even
though oxygen is available [33]. In agreement with these ﬁndings
in virally transformed cells, HPV-induced oncogenic transforma-
tion of cervical epithelium is associated with increased expression
of the glucose transporter GLUT1 [67]. Some studies have shown
that more aggressive tumors have a greater demand for metabolic
energy and hence for glucose. Accordingly, the expression level of
GLUT1 correlates reciprocally with the survival of cancer patients
[82]. A recent study has demonstrated a role for the sodium-cou-
pled glucose transporter SGLT1 in epithelial cancers [82]. The lev-
els of SGLT1 protein and its transport activity are elevated in
malignant epithelial cell lines by the co-expression of EGFR, which
stabilizes SGLT1 within the membrane. Overexpression of EGFR is
frequent in cervical cancer cells [25] as well as HPV-positive head
and neck tumors [45], providing a basis for exploiting the EGF
Fig. 1. Interference of high-risk genital a-HPV E6 and E7 proteins with the host cell cycle.
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might have immense clinical relevance. Small molecule tyrosine
kinase inhibitors show little efﬁcacy in the treatment of cancers
with high EGFR expression [25]. In contrast, antibodies directed
against the extracellular domain of EGFR may have the ability to
block the interaction of EGFR with SGLT1, thus blocking SGLT1-
mediated glucose entry into EGFR-positive cancer cells and eventu-
ally causing cell death [19]. Increased glucose uptake, however,
causes a signiﬁcant problem for the cell by decreasing the cellular
pH and potentially compromising cell survival unless other mech-
anisms counteract cellular acidiﬁcation. The growth factor-sensi-
tive sodium-proton exchanger NHE1 is a signiﬁcant mediator of
pH regulation in tumor cells (Fig. 2). This transporter pumps H+
out of the cells, coupled to a transmembrane Na+ gradient. The
activity of NHE1 is induced in several cancers by growth factors
such as EGF and, more importantly, by HPV oncoproteins. Cellular
transformation by the E7-protein was shown to require the stimu-
lation of NHE1 [9]. The regulatory factor of NHE1, called NHERF1,
recruits membrane receptors, transporters and cytoplasmic signal-
ing proteins into functional complexes, thereby increasing NHE1
activity. It was shown that HPV16 E6 degrades NHERF1 by a pro-
cess requiring the E6 PDZ domain and the ubiquitin ligase E6AP
[2]. Consistent with a manipulation of the cellular metabolism by
HPV oncoproteins, we have recently found that the E6-protein acti-
vates SGLT1 [49] and that PV-induced tumors in animals display a
high glucose uptake as shown by in vivo imaging techniques (Prob-
st et al. submitted for publication).
Beta-HPV-associated cancer development and therapy
A number of reports demonstrated that various nonmelanoma
skin cancer (NMSC) types contain DNA of beta (b)-HPV species 2Fig. 2. Effect of high-risk a-HPV E6 an[22]. While it is generally accepted that high-risk HPVs are causa-
tive for cervical, anogenital and some oropharyngeal cancers, the
etiological association of HPV and cutaneous cancers has not been
clearly demonstrated. Skin cancers based on HPV include cutane-
ous squamous cell carcinoma (cuSCC). Among the risk groups are
patients receiving immunosuppressive treatment or individuals
with acquired immunodeﬁciency syndrome who are generally
more susceptible to opportunistic infections. In addition, patients
presenting with epidermodysplasia verruciformis (EV) are at risk
of developing HPV-associated cutaneous malignancies. EV is a rare
genetically inherited skin disorder which is characterized by an
increased susceptibility of the skin to certain b-HPV types. These
include HPV 5, 8, 9, 12, 14, 15, 17, 19–25, 36–38, 46, 47, 49 and
50 and have been termed ‘‘EV-types’’ due to their increased occur-
rence in EV patients [13]. At least 30% of the affected individuals
will develop invasive squamous cell carcinomas and about 90% of
these tumors are associated with the HPV types 5 and 8 as high
copy numbers have been detected within tumor tissue [18].
Although a role of HPV in cutaneous cancer development seems
likely [3,31], HPV infection is not however sufﬁcient to induce can-
cerogenesis in EV patients. The vast majority of tumors develop on
sun-exposed skin and a role of ultraviolet (UV) radiation has been
demonstrated in a number of reports. Most recently Wallace and
co-workers showed that the HPV 5 and 8 E6 protein sensitizes
the cells to UVB exposure by disrupting the DNA double-strand
break repair mechanisms [81]. In addition, previous work showed
that the E6 protein of HPV types 1, 8 and 16 directly binds the DNA
repair protein XRCC1, which ultimately leads to a reduction of the
base excision repair pathway efﬁciency [32]. In line with the fact
that cutaneous HPV types are ubiquitously present on the human
skin, the impaired DNA repair activity may explain why immuno-
competent individuals are at risk of developing b-HPV-associatedd E7 on the glucose metabolism.
Fig. 3. Interference of high-risk cutaneous b-HPV E6 and E7 proteins with the host cell cycle.
400 Human papillomaviruses and cancerNMSCs upon local or systemic immunosuppression [22]. NMSC is
the most frequent human malignancy worldwide and its incidence
rate is continually rising. Clinical management of NMSC usually
involves surgical removal of the tumor tissue. Radiation therapy
may be employed as a primary or adjuvant treatment option of
persistent or recurrent advanced cancer lesions. More superﬁcial
cutaneous tumors may be treated by topical application of chemo-
therapeutic agents, laser therapy or intra-lesional interferon. Alter-
natively, novel immune-modulating agents such as imiquimod and
photodynamic therapy have also been proven effective [64].
Although surgery continues to be the most efﬁcient treatment
option, the search for less invasive therapies is on-going. A great
advantage of researching novel intervention points in HPV-associ-
ated NMSC is the availability of a well-established animal model
system. Infection of New Zealand White rabbits with the cottontail
rabbit papillomavirus (CRPV) results in papilloma development on
the skin of the animals within 4–6 weeks and invasive malignant
progression after 6–12 months post-infection [34,76,85]. Using
this in vivo system, the histone acetyltransferase p300 was recently
identiﬁed as a CRPV and b2-HPV 38 E6 interacting factor [60] sim-
ilar to the a-HPV E6 [86] rendering it a central cellular target for
both a- and b-HPV. This interaction was shown to disrupt p53
induced apoptosis [60]. However, unlike high-risk HPV E6, which
directly associates with p53 causing its degradation and low-risk
HPV E6 which binds p300 thereby blocking p53 acetylation neces-
sary for p53 stability, b-E6 appears to directly cause p300 degrada-
tion (Fig. 3). Recent publications of the group of Denise Galloway
have depicted this mechanism and its consequences in more detail
and found that p300 is subjected to proteasomal degradation upon
HPV 5, 8 and 38 E6 binding, which prevents its association with
AKT [29]. In uninfected cells AKT would phosphorylate p300 which
stabilizes the protein. Further research revealed that the down-
stream PI3 kinase family member ATR fails to phosphorylate p53
upon p300 degradation, which increases the UVB sensitivity of
infected cells and allows cell cycling despite damaged DNA [80].
In addition, b-HPV 38 E6 has been shown to indirectly reduce
p53 protein levels by accumulating the p53 inhibitor deltaNp73
[1]. Another difference between a- and b-E6 is the fact that unlike
high-risk a-HPV E6, b-HPV E6 does not contain a PDZ domain and
therefore cannot associate with PDZ-binding proteins. However,
both a- and b-E6 proteins share functions such as the activation
of the ribonucleoprotein telomerase [8,41] and the interaction with
host proteins including the E3 ubiquitin ligase E6AP [8,30,69] and
Bak [77–79] which plays a critical role in UV-induced apoptosis.Several b-E6 proteins target Bak for proteasomal degradation, thus
preventing apoptosis in UV-exposed keratinocytes [79]. The func-
tions exerted by the oncoprotein E7 of cutaneous HPV types are
similar to the activities of the mucosal HPV E7 protein [12], which
involves binding and degradation of pRB, thus inducing cell cycle
progression [73].
Conclusion
Altogether, there are clear functional differences between a-
and b-HPV oncologies, and also between high- and low-risk
viruses. The role of high-risk HPV types in cervical cancer and in
some tonsillar and oropharyngeal tumors has been well studied,
in fact most of the knowledge about HPV-dependent oncogenesis
originates from the high-risk types HPV 16 and 18. In contrast,
the causal relationship between NMSC and b-HPV remains to be
further established, but clinical studies are complicated by the
abundant presence of a large variety of HPV types on the normal
skin. Apart from anogenital, tonsillar and oropharyngeal tumors
and nonmelanoma skin cancer, HPV DNA has been detected in var-
ious other cancer types including cancers of the lung [75,80],
breast [23], brain [68] and bladder [74]. These reports, however,
are sparse and with the exception of bladder cancer, most of these
tumors were found to be metastases from previously identiﬁed
cervical or HPV-based head and neck carcinomas. Active transcrip-
tion of the high-risk HPV types was not observed in any of these
cases. The development and application of novel detection meth-
ods testing for both a- and b-viruses may reveal the true extent
of HPV-associated oncogenesis.
HPV is the most common sexually transmitted disease world-
wide and accounts for a signiﬁcant number of malignancies each
year. A widespread vaccination regime would help decrease the
burden, HPV infections inﬂict on public health systems. In addition,
the development of novel more targeted intervention therapies is
ongoing and promising candidate treatments include for example
therapeutic vaccines (reviewed by [58]).
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